GlassScriptPhysician profile
Michelle Yao
NPI 1699947499
$8,452.03
in general payments reported to CMS, 2019-2025
32 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $349 · 2021: $841 · 2022: $1,265 · 2023: $1,460 · 2024: $2,601 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,527 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,527.16 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,718.83 | 2022-2025 | Envista Mx60 Iol, Ic-8 Apthera Iol, Envista Aspire Iol |
| Alcon Vision LLC | $1,239.49 | 2019-2025 | Clareon, Simbrinza, Rocklatan |
| Mallinckrodt Hospital Products INC. | $724.55 | 2020-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $685.67 | 2019-2025 | Cequa, Xelpros |
| New World Medical,INC. | $587.28 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $365.42 | 2019-2023 | |
| Sight Sciences, INC. | $344.64 | 2022-2024 | Omni Surgical System, Tearcare System |
| Oyster Point Pharma, INC. | $298.00 | 2022-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $290.35 | 2019-2021 | |
| Abbvie INC. | $286.88 | 2022-2025 | Durysta |
| Glaukos Corporation | $272.21 | 2021-2025 | Idosetr |
| Astellas Pharma US INC | $254.71 | 2024-2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $222.69 | 2019-2021 | |
| Allergan, INC. | $181.74 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $168.25 | 2022-2023 | Tecnis Simplicity, Tecnis Iol |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $138.30 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $95.92 | 2021-2023 | Dextenza |
| Kala Pharmaceuticals, INC. | $94.65 | 2020-2021 | |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Harrow Eye, LLC | $54.06 | 2024-2025 | Vevye |
| Thea Pharma INC. | $49.29 | 2022-2024 | Iyuzeh |
| Lombart Brothers, INC. | $40.35 | 2025 | Opd-III |
| Rayner Intraocular Lenses Limited | $39.63 | 2022-2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Shire North American Group INC | $39.10 | 2019 | |
| Rxsight INC | $38.55 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Ani Pharmaceuticals, INC. | $26.06 | 2022 | |
| Dompe US, INC. | $25.99 | 2022 | |
| Amgen INC. | $24.86 | 2025 | Tepezza |
| Mallinckrodt Enterprises LLC | $23.74 | 2019 | |
| Eyepoint US, INC. | $22.39 | 2021 | |
| Horizon Therapeutics Plc | $17.86 | 2020 | |
| Eyevance Pharmaceuticals LLC | $15.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Yao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.